Copeptin testing in acute myocardial infarction: Ready for routine use?

Disease Markers

Volumn 2015, Issue , 2015, Pages

  Reinstadler, Sebastian Johannes ^a   Klug, Gert ^a   Feistritzer, Hans Josef ^a   Metzler, Bernhard ^a   Mair, Johannes ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COPEPTIN; TROPONIN T; GLYCOPEPTIDE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; CARDIOVASCULAR MAGNETIC RESONANCE; CAUSE OF DEATH; CORONARY ARTERY BYPASS GRAFT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HEART FUNCTION; HEART MUSCLE INJURY; HUMAN; LOW RISK PATIENT; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SUDDEN CARDIAC DEATH; ANIMAL; BLOOD; EVALUATION STUDY; GENETICS; HEART INFARCTION; METABOLISM;

ANIMALS; BIOMARKERS; EVALUATION STUDIES AS TOPIC; GLYCOPEPTIDES; HUMANS; MYOCARDIAL INFARCTION;

EID: 84928963539     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2015/614145     Document Type: Review

References (112)

1. K. Thygesen, J. S. Alpert, A. S. Jaffe et al., "Third universal definition of myocardial infarction, " European Heart Journal, vol. 33, no. 20, pp. 2551-2567, 2012.
2. T. Reichlin, W. Hochholzer, S. Bassetti et al., "Early diagnosis of myocardial infarction with sensitive cardiac troponin assays, " New England Journal of Medicine, vol. 361, no. 9, pp. 858-867, 2009.
3. T. Keller, T. Zeller, D. Peetz et al., "Sensitive troponin I assay in early diagnosis of acute myocardial infarction, " The New England Journal of Medicine, vol. 361, no. 9, pp. 868-877, 2009.
4. J. Mair, "High-sensitivity cardiac troponins in everyday clinical practice, " World Journal of Cardiology, vol. 6, no. 4, pp. 175-182, 2014.
5. C. W. Hamm, J.-P. Bassand, S. Agewall et al., "ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC), " European Heart Journal, vol. 32, no. 23, pp. 2999-3054, 2011.
6. C. Mueller, "Biomarkers and acute coronary syndromes: an update, " European Heart Journal, vol. 35, no. 9, pp. 552-556, 2014.
7. S. K. James, B. Lindahl, A. Siegbahn et al., "N-terminal probrain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a global utilization of strategies to open occluded arteries (GUSTO)-IV substudy, " Circulation, vol. 108, no. 3, pp. 275-281, 2003.
8. C. W. Hamm, B. U. Goldmann, C. Heeschen, G. Kreymann, J. Berger, and T. Meinertz, "Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I, "The New England Journal ofMedicine, vol. 337, no. 23, pp. 1648-1653, 1997.
9. G. Klug, A. Mayr, J. Mair et al., "Role of biomarkers in assessment of early infarct size after successful p-PCI for STEMI, " Clinical Research in Cardiology, vol. 100, no. 6, pp. 501-510, 2011.
10. M. Furtner, T. Ploner, A. Hammerer-Lercher, R. Pechlaner, and J. Mair, "The high-sensitivity cardiac troponin T assay is superior to its previous assay generation for prediction of 90-day clinical outcome in ischemic stroke, " Clinical Chemistry and Laboratory Medicine, vol. 50, no. 11, pp. 2027-2029, 2012.
11. G. E. Cramer, M. A. Brouwer, H. L. Vader et al., "Highly sensitive cardiac troponin T and long-term mortality in a population of community-derived perimenopausal women: nested case-control study, " Heart, vol. 99, no. 8, pp. 528-533, 2013.
12. T. Kubo, H. Kitaoka, S. Yamanaka et al., "Significance of highsensitivity cardiac troponin T in hypertrophic cardiomyopathy, " Journal of theAmericanCollege of Cardiology, vol. 62, no. 14, pp. 1252-1259, 2013.
13. A. M. C. Neukamm, A. D. Høiseth, T.-A. Hagve, V. Søyseth, and T. Omland, "High-sensitivity cardiac troponin T levels are increased in stable COPD, " Heart, vol. 99, no. 6, pp. 382-387, 2013.
14. A. Dispenzieri, M. A. Gertz, S. K. Kumar et al., "High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis, " Heart, vol. 100, no. 5, pp. 383-388, 2014.
15. A. Mayr, J. Mair, M. Schocke et al., "Predictive value of NTpro BNP after acute myocardial infarction: relation with acute and chronic infarct size andmyocardial function, " International Journal of Cardiology, vol. 147, no. 1, pp. 118-123, 2011.
16. K. Thygesen, J. Mair, C. Mueller et al., "Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care, " European Heart Journal, vol. 33, no. 16, pp. 2001-2006, 2012.
17. D. A. Morrow, N. Rifai, E. M. Antman et al., "C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy, " Journal of the American College of Cardiology, vol. 31, no. 7, pp. 1460-1465, 1998.
18. K. Thygesen, J. Mair, E. Giannitsis et al., "How to use high-sensitivity cardiac troponins in acute cardiac care, " European Heart Journal, vol. 33, no. 18, pp. 2252-2257, 2012.
19. A. Mayr, G. Klug, M. Schocke et al., "Late microvascular obstruction after acutemyocardial infarction: relation with cardiac and inflammatory markers, " International Journal of Cardiology, vol. 157, no. 3, pp. 391-396, 2012.
20. R. G. O'Malley, M. P. Bonaca, B. M. Scirica et al., "Prognostic performance of multiple biomarkers in patients with non-STsegment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis in Myocardial Infarction 36), " Journal of the American College of Cardiology, vol. 63, no. 16, pp. 1644-1653, 2014.
21. R. A. P. Weir, A. M. Miller, G. E. J. Murphy et al., "Serumsoluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction, " Journal of the American College of Cardiology, vol. 55, no. 3, pp. 243-250, 2010.
22. G. Klug, H. J. Feistritzer, S. J. Reinstadler et al., "Association of aortic stiffness with biomarkers of myocardial wall stress after myocardial infarction, " International Journal of Cardiology, vol. 173, no. 2, pp. 253-258, 2014.
23. M. Reiter, R. Twerenbold, T. Reichlin et al., "Heart-type fatty acid-binding protein in the early diagnosis of acute myocardial infarction, " Heart, vol. 99, no. 10, pp. 708-714, 2013.
24. S. J. Reinstadler, G. Klug, H. J. Feistritzer et al., "Relation of plasma adiponectin levels and aortic stiffness after acute STsegment elevationmyocardial infarction, " European Heart Journal: Acute Cardiovascular Care, vol. 3, no. 1, pp. 10-17, 2014.
25. F. Cappellini, S. Da Molin, S. Signorini et al., "Heart-type fatty acid-binding protein may exclude acute myocardial infarction on admission to emergency department for chest pain, " Acute Cardiac Care, vol. 15, no. 4, pp. 83-87, 2013.
26. M. J. Brownstein, J. T. Russell, and H. Gainer, "Synthesis, transport and release of posterior pituitary hormones, " Science, vol. 207, no. 4429, pp. 373-378, 1980.
27. C. P. Mahoney, E. Weinberger, C. Bryant, M. Ito, and J. L. Jameson, "Effects of aging on vasopressin production in a kindred with autosomal dominant neurohypophyseal diabetes insipidus due to the Deltae47 neurophysin mutation, " Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 2, pp. 870-876, 2002.
28. C. Barat, L. Simpson, and E. Breslow, "Properties of human vasopressin precursor constructs: inefficient monomer folding in the absence of copeptin as a potential contributor to diabetes insipidus, " Biochemistry, vol. 43, no. 25, pp. 8191-8203, 2004.
29. N. G. Morgenthaler, J. Struck, S. Jochberger, and M. W. Dünser, "Copeptin: clinical use of a new biomarker, " Trends in Endocrinology and Metabolism, vol. 19, no. 2, pp. 43-49, 2008.
30. G. L. Robertson, E. A. Mahr, S. Athar, and T. Sinha, "Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma, " The Journal of Clinical Investigation, vol. 52, no. 9, pp. 2340-2352, 1973.
31. N. G. Morgenthaler, J. Struck, C. Alonso, and A. Bergmann, "Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin, " Clinical Chemistry, vol. 52, no. 1, pp. 112-119, 2006.
32. J. J. Preibisz, J. E. Sealey, J. H. Laragh, R. J. Cody, and B. B. Weksler, "Plasma and platelet vasopressin in essential hypertension and congestive heart failure, " Hypertension, vol. 5, no. 2, part 2, pp. I129-I138, 1983.
33. M. Katan and M. Christ-Crain, "The stress hormone copeptin: a new prognostic biomarker in acute illness, " Swiss Medical Weekly, vol. 140, articlew13101, 2010.
34. B. Müller, N. Morgenthaler, D. Stolz et al., "Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections, " European Journal of Clinical Investigation, vol. 37, no. 2, pp. 145-152, 2007.
35. N. G. Morgenthaler, B. Müller, J. Struck, A. Bergmann, H. Redl, andM. Christ-Crain, "Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock, " Shock, vol. 28, no. 2, pp. 219-226, 2007.
36. M. Katan, F. Fluri, N. G. Morgenthaler et al., "Copeptin: a novel, independent prognosticmarker in patientswith ischemic stroke, " Annals of Neurology, vol. 66, no. 6, pp. 799-808, 2009.
37. G. Sang, J.-M. Du, Y.-Y. Chen, Y.-B. Chen, J.-X. Chen, and Y.-C. Chen, "Plasma copeptin levels are associated with prognosis of severe acute pancreatitis, " Peptides, vol. 51, pp. 4-8, 2014.
38. S. Q. Khan, O. S. Dhillon, R. J. O'Brien et al., "C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: leicester acute myocardial infarction peptide (LAMP) study, " Circulation, vol. 115, no. 16, pp. 2103-2110, 2007.
39. M. Katan, N. Morgenthaler, I. Widmer et al., "Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level, " Neuroendocrinology Letters, vol. 29, no. 3, pp. 341-346, 2008.
40. Y. L. Gu, A. A. Voors, F. Zijlstra et al., "Comparison of the temporal release pattern of copeptin with conventional biomarkers in acute myocardial infarction, " Clinical Research in Cardiology, vol. 100, no. 12, pp. 1069-1076, 2011.
41. G. Szinnai, N. G. Morgenthaler, K. Berneis et al., "Changes in plasma copeptin, the C-terminal portion of arginine vasopressin duringwater deprivation and excess in healthy subjects, " The Journal of Clinical Endocrinology &Metabolism, vol. 92, no. 10, pp. 3973-3978, 2007.
42. H. Hupf, D. Grimm, G. A. J. Riegger, and H. Schunkert, "Evidence for a vasopressin system in the rat heart, " Circulation Research, vol. 84, no. 3, pp. 365-370, 1999.
43. C. Liebetrau, H. Nef, S. Szardien et al., "Release kinetics of copeptin in patients undergoing transcoronary ablation of septal hypertrophy, " Clinical Chemistry, vol. 59, no. 3, pp. 566-569, 2013.
44. S. J. Reinstadler, G. Klug, H.-J. Feistritzer et al., "Long-term predictive value of copeptin after acutemyocardial infarction: a cardiacmagnetic resonance study, " International Journal of Cardiology, vol. 172, no. 2, pp. e359-e360, 2014.
45. S. J. Reinstadler, G. Klug, H.-J. Feistritzer et al., "Association of copeptin with myocardial infarct size and myocardial function after ST segment elevation myocardial infarction, " Heart, vol. 99, no. 20, pp. 1525-1529, 2013.
46. F. Stallone, R. Twerenbold, K. Wildi et al., "Prevalence, characteristics and outcome of non-cardiac chest pain and elevated copeptin levels, " Heart, vol. 100, no. 21, pp. 1708-1714, 2014.
47. T. Reichlin, W. Hochholzer, C. Stelzig et al., "Incremental value of copeptin for rapid rule out of acute myocardial infarction, " Journal of the American College of Cardiology, vol. 54, no. 1, pp. 60-68, 2009.
48. T. Keller, S. Tzikas, T. Zeller et al., "Copeptin improves early diagnosis of acute myocardial infarction, " Journal of the American College of Cardiology, vol. 55, no. 19, pp. 2096-2106, 2010.
49. M. J. Lipinski, R. O. Escárcega, F. D'Ascenzo et al., "A systematic review and collaborative meta-analysis to determine the incremental value of copeptin for rapid rule-out of acute myocardial infarction, " The American Journal of Cardiology, vol. 113, no. 9, pp. 1581-1591, 2014.
50. T. Raskovalova, R. Twerenbold, P. O. Collinson et al., "Diagnostic accuracy of combined cardiac troponin and copeptin assessment for early rule-out ofmyocardial infarction: a systematic review and meta-analysis, " European Heart Journal: Acute Cardiovascular Care, vol. 3, no. 1, pp. 18-27, 2014.
51. S. von Haehling, J. Papassotiriou, N. G. Morgenthaler et al., "Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease, " International Journal of Cardiology, vol. 162, no. 1, pp. 27-32, 2012.
52. A. Gegenhuber, J. Struck, B. Dieplinger et al., "Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure, " Journal of Cardiac Failure, vol. 13, no. 1, pp. 42-49, 2007.
53. S. Neuhold, M. Huelsmann, G. Strunk et al., "Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease, " Journal of the American College of Cardiology, vol. 52, no. 4, pp. 266-272, 2008.
54. H. Bosselmann, M. Egstrup, K. Rossing et al., "Prognostic significance of cardiovascular biomarkers and renal dysfunction in outpatients with systolic heart failure: a long term follow-up study, " International Journal of Cardiology, vol. 170, no. 2, pp. 202-207, 2013.
55. L. Balling, C. Kistorp, M. Schou et al., "Plasma copeptin levels and prediction of outcome in heart failure outpatients: relation to hyponatremia and loop diuretic doses, " Journal of Cardiac Failure, vol. 18, no. 5, pp. 351-358, 2012.
56. A. Maisel, Y. Xue, K. Shah et al., "Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study, " Circulation: Heart Failure, vol. 4, no. 5, pp. 613-620, 2011.
57. D. Bar-Shalom, M. K. Poulsen, L. M. Rasmussen et al., "Plasma copeptin asmarker of cardiovascular disease in asymptomatic type 2 diabetes patients, " Diabetes and Vascular Disease Research, vol. 11, no. 6, pp. 448-450, 2014.
58. G. Velho, N. Bouby, S. Hadjadj et al., "Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria, " Diabetes Care, vol. 36, no. 11, pp. 3639-3645, 2013.
59. I. J. Riphagen, W. E. Boertien, A. Alkhalaf et al., "Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular and all-cause mortality in patients with type 2 diabetes (ZODIAC-31), " Diabetes Care, vol. 36, no. 10, pp. 3201-3207, 2013.
60. R. Seligman, J. Papassotiriou, N. G. Morgenthaler, M. Meisner, and P. J. Z. Teixeira, "Copeptin, a novel prognostic biomarker in ventilator-associated pneumonia, " Critical Care, vol. 12, no. 1, article R11, 2008.
61. M. Kolditz, M. Halank, B. Schulte-Hubbert, S. Bergmann, S. Albrecht, and G. Höffken, "Copeptin predicts clinical deterioration and persistent instability in community-acquired pneumonia, " RespiratoryMedicine, vol. 106, no. 9, pp. 1320-1328, 2012.
62. D. Stolz, M. Christ-Crain, N. G. Morgenthaler et al., "Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD, " Chest, vol. 131, no. 4, pp. 1058-1067, 2007.
63. Q. Zhang, G. Dong, X. Zhao, M. Wang, and C. S. Li, "Prognostic significance of hypothalamic-pituitary-adrenal axis hormones in early sepsis: a study performed in the emergency department, " Intensive Care Medicine, vol. 40, no. 10, pp. 1499-1508, 2014.
64. P. Ostadal, A. Kruger, V. Zdrahalova et al., "Blood levels of copeptin on admission predict outcomes in out-of-hospital cardiac arrest survivors treated with therapeutic hypothermia, " Critical Care, vol. 16, no. 5, article R187, 2012.
65. N. P. Nickel, R. Lichtinghagen, H. Golpon et al., "Circulating levels of copeptin predict outcome in patients with pulmonary arterial hypertension, " Respiratory Research, vol. 14, no. 1, article 130, 2013.
66. G. M. De Marchis, A. Weck, H. Audebert et al., "Copeptin for the prediction of recurrent cerebrovascular events after transient ischemic attack: results fromtheCoRisk study, " Stroke, vol. 45, no. 10, pp. 2918-2923, 2014.
67. W.-J. Tu, X. Dong, S.-J. Zhao, D.-G. Yang, and H. Chen, "Prognostic value of plasma neuroendocrine biomarkers in patients with acute ischaemic stroke, " Journal of Neuroendocrinology, vol. 25, no. 9, pp. 771-778, 2013.
68. J.-L. Zhang, C.-H. Yin, Y. Zhang, L.-B. Zhao, H.-J. Fu, and J.-C. Feng, "Plasma copeptin and long-term outcomes in acute ischemic stroke, " Acta Neurologica Scandinavica, vol. 128, no. 6, pp. 372-380, 2013.
69. D. B. Yang, W. H. Yu, X. Q. Dong et al., "Plasma copeptin level predicts acute traumatic coagulopathy and progressive hemorrhagic injury after traumatic brain injury, " Peptides, vol. 58, pp. 26-29, 2014.
70. G.-F. Yu, Q. Huang, W.-M. Dai et al., "Prognostic value of copeptin: one-year outcome in patients with traumatic brain injury, " Peptides, vol. 33, no. 1, pp. 164-169, 2012.
71. X. Q. Dong, M. Huang, S. B. Yang, W. H. Yu, and Z. Y. Zhang, "Copeptin is associated with mortality in patients with traumatic brain injury, " Journal of Trauma-Injury, Infection and Critical Care, vol. 71, no. 5, pp. 1194-1198, 2011.
72. W.-H. Yu, W.-H. Wang, X.-Q. Dong et al., "Prognostic significance of plasma copeptin detection compared with multiple biomarkers in intracerebral hemorrhage, " Clinica Chimica Acta, vol. 433, pp. 174-178, 2014.
73. Z. J. Wei, Y. Q. Ou, X. Li, andH. Li, "The 90-dayprognostic value of copeptin in acute intracerebral hemorrhage, " Neurological Sciences, vol. 35, no. 11, pp. 1673-1679, 2014.
74. V. Maravic-Stojkovic, L. J. Lausevic-Vuk, M. Obradovic et al., "Copeptin level after carotid endarterectomy and perioperative stroke, " Angiology, vol. 65, no. 2, pp. 122-129, 2014.
75. S. Dong, C. L. Li, W. D. Liang, M. H. Chen, Y. T. Bi, and X. W. Li, "Postoperative plasma copeptin levels independently predict deliriumand cognitive dysfunction after coronary artery bypass graft surgery, " Peptides, vol. 59, pp. 70-74, 2014.
76. X. Li, X.-C. Yang, Q.-M. Sun, X.-D. Chen, and Y.-C. Li, "Brain natriuretic peptide and copeptin levels are associated with cardiovascular disease in patients with chronic kidney disease, " Chinese Medical Journal, vol. 126, no. 5, pp. 823-827, 2013.
77. W. E. Boertien, E. Meijer, D. Zittema et al., "Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease, " Nephrology Dialysis Transplantation, vol. 27, no. 11, pp. 4131-4137, 2012.
78. D. Zittema, W. E. Boertien, A. P. van Beek et al., "Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment, " Clinical Journal of the American Society of Nephrology, vol. 7, no. 6, pp. 906-913, 2012.
79. L. Pang, H. L. Wang, Z. H. Wang et al., "Plasma copeptin as a predictor of intoxication severity and delayed neurological sequelae in acute carbonmonoxide poisoning, " Peptides, vol. 59, pp. 89-93, 2014.
80. B. Karbek, M. Ozbek, M. Karakose et al., "Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular risk in patients with polycystic ovary syndrome, " Journal of Ovarian Research, vol. 7, no. 1, article 31, 2014.
81. A. Tuten, M. Kucur, M. Imamoglu et al., "Copeptin is associated with the severity of endometriosis, " Archives of Gynecology and Obstetrics, vol. 290, no. 1, pp. 75-82, 2014.
82. E. H. Yeung, A. Liu, J. L. Mills et al., "Increased levels of copeptin before clinical diagnosis of preelcampsia, " Hypertension, vol. 64, no. 6, pp. 1362-1367, 2014.
83. E. Zulfikaroglu, M. Islimye, E. A. Tonguc et al., "Circulating levels of copeptin, a novel biomarker in pre-eclampsia, " The Journal of Obstetrics and Gynaecology Research, vol. 37, no. 9, pp. 1198-1202, 2011.
84. F. K. Isman, B. Zulfikaroglu, B. Isbilen et al., "Copeptin is a predictive biomarker of severity in acute pancreatitis, "American Journal of EmergencyMedicine, vol. 31, no. 4, pp. 690-692, 2013.
85. J.-P. Moreno, E. Grandclement, E. Monnet et al., "Plasma copeptin, a possible prognosticmarker in cirrhosis, " Liver International, vol. 33, no. 6, pp. 843-851, 2013.
86. K. S. Akinlade, A. D. Atere, S. K. Rahamon, and J. A. Olaniyi, "Serum levels of copeptin, C-reactive protein and cortisol in different severity groups of sickle cell anaemia, " Nigerian Journal of Physiological Sciences, vol. 28, no. 2, pp. 159-164, 2013.
87. C. Meune, S. Zuily, K. Wahbi, Y.-E. Claessens, S. Weber, and C. Chenevier-Gobeaux, "Combination of copeptin and highsensitivity cardiac troponin T assay in unstable angina and non-ST-segment elevationmyocardial infarction: a pilot study, " Archives of Cardiovascular Diseases, vol. 104, no. 1, pp. 4-10, 2011.
88. E. Giannitsis, T. Kehayova, M. Vafaie, and H. A. Katus, "Combined testing of high-sensitivity troponin T and copeptin on presentation at prespecified cutoffs improves rapid rule-out of non-ST-segment elevation myocardial infarction, " Clinical Chemistry, vol. 57, no. 10, pp. 1452-1455, 2011.
89. P. Ray, S. Charpentier, C. Chenevier-Gobeaux et al., "Combined copeptin and troponin to rule out myocardial infarction in patients with chest pain and a history of coronary artery disease, " The American Journal of Emergency Medicine, vol. 30, no. 3, pp. 440-448, 2012.
90. A. Maisel, C. Mueller, S.-X. Neath et al., "Copeptin helps in the early detection of patients with acutemyocardial infarction: primary results of the CHOPIN trial (Copeptin Helps in the early detection of Patients with acute myocardial INfarction), " Journal of the American College of Cardiology, vol. 62, no. 2, pp. 150-160, 2013.
91. M. Sebbane, S. Lefebvre, N. Kuster et al., "Early rule out of acute myocardial infarction in ED patients: Value of combined highsensitivity cardiac troponin T and ultrasensitive copeptin assays at admission, "TheAmerican Journal of EmergencyMedicine, vol. 31, no. 9, pp. 1302-1308, 2013.
92. C. Chenevier-Gobeaux, Y. Freund, Y.-E. Claessens et al., "Copeptin for rapid rule out of acute myocardial infarction in emergency department, " International Journal of Cardiology, vol. 166, no. 1, pp. 198-204, 2013.
93. J. Thelin, C. Borna, D. Erlinge, and B. O hlin, "The combination of high sensitivity troponin T and copeptin facilitates early ruleout of ACS: a prospective observational study, " BMC Cardiovascular Disorders, vol. 13, article 42, 2013.
94. C. Balmelli, C. Meune, R. Twerenbold et al., "Comparisonof the performances of cardiac troponins, including sensitive assays, and copeptin in the diagnostic of acute myocardial infarction and long-term prognosis between women and men, " American Heart Journal, vol. 166, no. 1, pp. 30-37, 2013.
95. P. Collinson, D. Gaze, and S. Goodacre, "Comparison of contemporary troponin assays with the novel biomarkers, heart fatty acid binding protein and copeptin, for the early confirmation or exclusion ofmyocardial infarction in patients presenting to the emergency department with chest pain, " Heart, vol. 100, no. 2, pp. 140-145, 2014.
96. J. Duchenne, S. Mestres, and N. Dublanchet, "Diagnostic accuracy of copeptin sensitivity and specificity in patients with suspected non-ST-elevation myocardial infarction with troponin I below the 99th centile at presentation, " BMJ Open, vol. 4, no. 3, Article ID e004449corr1, 2014.
97. P. Llorens, M. Sánchez, P. Herrero, F. J. Martń-Sánchez, P. Piñera, and Ò. Miró, "The utility of copeptin in the emergency department for non-ST-elevation myocardial infarction rapid rule out: COPED-MIRRO study, " European Journal of Emergency Medicine, vol. 21, no. 3, pp. 220-229, 2014.
98. M. Karakas, J. L. Januzzi Jr., J. Meyer et al., "Copeptin does not add diagnostic information to high-sensitivity troponin t in low-to intermediate-risk patients with acute chest pain: results from the rule out myocardial infarction by computed tomography (ROMICAT) Study, " Clinical Chemistry, vol. 57, no. 8, pp. 1137-1145, 2011.
99. S. Charpentier, B. Lepage, F. Maupas-Schwalm et al., "Copeptin improves the diagnostic performance of sensitive troponin Iultra but cannot rapidly rule out non-ST-elevation myocardial infarction at presentation to an emergency department, " Annals of Emergency Medicine, vol. 61, no. 5, pp. 549. e1-558. e1, 2013.
100. M. Weber, O. Bazzino, J. L. N. Estrada et al., "Improved diagnostic and prognostic performance of a new high-sensitive troponin T assay in patients with acute coronary syndrome, " The American Heart Journal, vol. 162, no. 1, pp. 81-88, 2011.
101. T. Keller, T. Zeller, F. Ojeda et al., "Serial changes in highly sensitive troponin I assay and early diagnosis ofmyocardial infarction, " Journal of the American Medical Association, vol. 306, no. 24, pp. 2684-2693, 2011.
102. R. Body, S. Carley, G. McDowell et al., "Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a high-sensitivity assay, " Journal of the American College of Cardiology, vol. 58, no. 13, pp. 1332-1339, 2011.
103. N. Bandstein, R. Ljung, M. Johansson, and M. J. Holzmann, "Undetectable high-sensitivity cardiac troponin T level in the emergency department and risk of myocardial infarction, " Journal of the American College of Cardiology, vol. 63, no. 23, pp. 2569-2578, 2014.
104. M. Mockel, J. Searle, C. Hamm et al., "Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study, " European Heart Journal, 2014.
105. P. Collinson, S. Goodacre, D. Gaze, and A. Gray, "Very early diagnosis of chest pain by point-of-care testing: comparison of the diagnostic efficiency of a panel of cardiac biomarkers compared with troponin measurement alone in the RATPAC trial, " Heart, vol. 98, no. 4, pp. 312-318, 2012.
106. M. Than, L. Cullen, C. M. Reid et al., "A 2-h diagnostic protocol to assess patients with chest pain symptoms in the Asia-Pacific region (ASPECT): a prospective observational validation study, " The Lancet, vol. 377, no. 9771, pp. 1077-1084, 2011.
107. D. Kelly, I. B. Squire, S. Q. Khan et al., "C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction, " Journal of Cardiac Failure, vol. 14, no. 9, pp. 739-745, 2008.
108. M. Möckel and J. Searle, "The positive predictive value of ctproAVP (copeptin) in patients with STEMI, " Heart, vol. 99, no. 20, p. 1475, 2013.
109. H. Narayan, O. S. Dhillon, P. A. Quinn et al., "C-terminal provasopressin (copeptin) as a prognostic marker after acute non-ST elevation myocardial infarction: leicester acute myocardial infarction peptide II (LAMP II) study, " Clinical Science, vol. 121, no. 2, pp. 79-89, 2011.
110. D. Afzali, M. Erren, H. J. Pavenstädt et al., "Impact of copeptin on diagnosis, risk stratification, and intermediate-term prognosis of acute coronary syndromes, " Clinical Research in Cardiology, vol. 102, no. 10, pp. 755-763, 2013.
111. M. Sanchez, P. Llorens, P. Herrero, F. J. Martin-Sanchez, P. Pinera, and O. Miro, "The utility of copeptin in the emergency department as a predictor of adverse outcomes in non-ST-elevation acute coronary syndrome: the COPED-PAO study, " Emergency Medicine Journal, vol. 31, no. 4, pp. 286-291, 2014.
112. M. Potocki, T. Reichlin, S. Thalmann et al., "Diagnostic and prognostic impact of copeptin and high-sensitivity cardiac troponin T in patients with pre-existing coronary artery disease and suspected acute myocardial infarction, " Heart, vol. 98, no. 7, pp. 558-565, 2012.